Radiopharm Prices $4.05M Registered Direct Offering at a 26% Discount, Adding Warrants
RADX sits 20% above its 52-week low of $2.73 on elevated volume (29× avg).
Summary
Radiopharm Theranostics priced a $4.05 million registered direct offering at a 26% discount to market, with attached warrants, raising $3.3 million net for clinical programs.
Key Events · Financing and Capital Events · RADX
-
Offering Priced at Deep Discount
The company offered 1,281,646 ADSs at $3.16 per ADS, a 26% discount to the July 21 closing price of $4.29, for gross proceeds of $4.05 million.
-
Warrants Add Dilution Overhang
Investors receive warrants to purchase up to 1,281,646 ADSs at $3.79 per ADS, exercisable after shareholder approval and expiring July 31, 2029.
-
Net Proceeds of $3.3 Million
After placement agent fees of 7% of gross proceeds and estimated expenses, the company expects to receive approximately $3.3 million.
-
Use of Proceeds for Clinical Programs
Funds will support preparation for the RAD101 Phase 3 study, completion of RAD204 dose escalation, and advancement of other therapeutic programs.
Analysis · RADX · Life Sciences
Radiopharm Theranostics finalized a registered direct offering of 1.28 million ADSs at $3.16 per share, a steep 26% discount to the last close of $4.29. The deal raises approximately $3.3 million in net proceeds, but the discount and attached warrants signal weak demand and potential overhang. The concurrent private placement of warrants exercisable at $3.79 adds further dilution risk. This follows a series of capital raises, including a recent ATM amendment and a concurrent Australian placement, suggesting the company is aggressively funding its pipeline amid cash burn.
At the time of this filing, RADX was trading at $3.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47M. The 52-week trading range was $2.73 to $16.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.